Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Supernus Pharmaceuticals, Inc. (SUPN) had Stock-Based Compensation of $20.12M for the most recently reported fiscal quarter, ending 2024-09-30.
| Income Statement Financials | |
$175.69M |
|
$38.50M |
|
$17.58M |
|
$158.11M |
|
$134.84M |
|
$40.84M |
|
$4.10M |
|
$44.94M |
|
$44.94M |
|
$38.50M |
|
$38.50M |
|
$38.50M |
|
$38.50M |
|
$40.84M |
|
$61.91M |
|
55.15M |
|
56.02M |
|
$0.70 |
|
$0.69 |
|
| Balance Sheet Financials | |
$640.00M |
|
$11.88M |
|
$702.70M |
|
$1.34B |
|
$291.51M |
|
-- |
|
$44.04M |
|
$335.55M |
|
$1.01B |
|
$349.98M |
|
$1.01B |
|
55.22M |
|
| Cash Flow Statement Financials | |
$127.55M |
|
$-177.23M |
|
$6.30M |
|
$75.05M |
|
$31.67M |
|
$-43.38M |
|
|
Stock-Based Compensation |
$20.12M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
89.99% |
|
23.25% |
|
23.25% |
|
-- |
|
25.58% |
|
21.91% |
|
$127.03M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.27 |
|
1.21 |
|
74.49 |
|
3.82% |
|
11.00% |
|
2.87% |
|
3.82% |
|
$18.24 |
|
$2.27 |
|
$2.28 |
|